Bristol-Myers Squibb Co. reported once again that the combination of its blockbuster PD-1 inhibitor Opdivo (nivolumab) and CTLA-4 inhibitor Yervoy (ipilimumab) did not achieve statistical significance in a Phase III clinical trial – at least in terms of progression-free survival – but the ongoing first-line renal cell carcinoma (RCC) trial still could yield significant results in overall survival.
This is the second Phase III disappointment this year for Opdivo plus Yervoy after Bristol revealed in April that the...







![Spotlight On RDCs, AOCs As Leading Novel Bioconjugates[Updated]](https://web.insights.norstella-labs.com/resizer/v2/3M7ZAWZOBNK7NG4A4WDOIFG6DU.jpg?smart=true&auth=392a1fdb3cfacb29445720c412410e598dbcc5f90f14857652cd498bd0faa0fb&width=400&height=225)